2015 American Transplant Congress
CD28 Saturation by FR104, a Non-Activating CD28 Antagonist Fab in a Non-Human Primate Cardiac Allograft Model
Background: Targeting CD28 costimulation pathway with a selective antagonist is a promising approach in tolerance induction. The extent to which novel therapeutic antibodies reach their…2015 American Transplant Congress
Selective CD28 Blockade With or Without CD40-CD154 Blockade Promotes Cardiac Allograft Protection in Non-Human Primates
1Surgery, University of Maryland School of Medicine, Baltimore, MD; 2INSERM, U643, Nants, France.
Aim: Selective targeting CD28:B7 costimulation without interfering with CTLA-4-dependent immune regulation is theoretically an attractive approach to modulate pathogenic T cell-dependent immunity. We previously reported…2015 American Transplant Congress
Costimulation Blockade and Bortezomib to Desensitize Rhesus Macaque and Prolong Renal Allograft Survival
Surgery, Emory Transplant Center, Atlanta, GA.
[Background] Preformed donor specific antibody (DSA) due to prior sensitization affects a significant population of transplant patients, portending a poorer prognosis in short- and long-term…2015 American Transplant Congress
CTLA4Ig Administered During T-Cell Priming Negates de novo Alloantibody Responses and Modulates Recall Antibody Production
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Arcadia, CA.
Background CTLA4Ig (Belatacept) is a novel anti-rejection therapy aimed at costimulatory blockade. Clinical data suggest that post-transplant alloantibody formation is also reduced in patients treated…2015 American Transplant Congress
Regulatory T Cells Expanded by Activated iNKT Cells Facilitate Migration of Donor Dendritic Cells Into the Recipient Thymus and Subsequent Establishment of Clonal Deletion
We previously reported that combination therapy using liposomal α-galactosylceramide (lipo-αGC) and anti-CD154 mAb could expand regulatory T cells (Tregs) in vivo through activation of the…2015 American Transplant Congress
Immunosuppression With Anti-CD40 mAb and Rapamycin for Islet and Kidney Co-Transplantation in Nonhuman Primates
Transplant Center, Massachusetts General Hospital, Boston, MA.
Background: For patients with end-stage renal disease secondary to type 1 diabetes mellitus, islet and kidney co-transplantation can be an ideal transplant option. However, a…2015 American Transplant Congress
Distinct Roles of CD137 and CD137L Bi-Directional Signaling in Candida albicans Infection
Invasive fungal infections by Candida albicans frequently cause mortality in immunocompromised patients, yet the cellular processes leading to this mortality remain ill-defined. Here, using genetic…2015 American Transplant Congress
Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated With Belatacept
Introduction: Focal segmental glomerulosclerosis (FSGS) is a cause of end-stage renal failure that frequently recurs following renal transplant, often leading to early allograft loss. A…2015 American Transplant Congress
Primary and Secondary Vaccine Responses in a Non-Human Primate Model of Cardiac Allotransplantation
Purpose: To compare the effect of calcineurin- versus costimulation-based immunosuppression on primary and secondary vaccine responses in non-human primate heart transplant recipients.Background: Antibody response following…2015 American Transplant Congress
CFZ533: Assessment of Immunomodulatory Activity Following Single Doses of a Novel Anti-CD40 mAb in Healthy Volunteers
Blocking the CD40-CD154 pathway has been shown to effectively prolong renal allograft survival in non-human primates. CFZ533 is a novel, fully human, Fc-silent, anti-CD40 monoclonal…
American Transplant Congress abstracts